Published April 12, 2021
| Version v1
Journal article
Open
<scp>Daratumumab, lenalidomide, and dexamethasone</scp> in systemic <scp>light‐chain</scp> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
Authors/Creators
- 1. Division of Hematology/Oncology, Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany; Amyloidosis Center, Heidelberg University Hospital Heidelberg Germany; Department of Oncology and Hematology, Klinikum Oldenburg University Clinic Oldenburg Germany
- 2. Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Germany
- 3. Hematology/Oncology practice Hämatologisch‐Onkologische Praxis Altona Hamburg Germany
- 4. Department of Hematology University Hospital Essen Essen Germany
- 5. Division of Hematology/Oncology, Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany; Amyloidosis Center, Heidelberg University Hospital Heidelberg Germany
- 6. Institute of Human Genetics University Heidelberg Heidelberg Germany
- 7. Division of Hematology/Oncology, Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany
- 8. Division of Hematology/Oncology, Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany; Amyloidosis Center, Heidelberg University Hospital Heidelberg Germany; Amyloidosis Research and Treatment Center, IRCCS Policlinico San Matteo University of Pavia Pavia Italy; Department of Molecular Medicine University of Pavia Pavia Italy
- 9. Division of Hematology/Oncology, Department of Internal Medicine V Heidelberg University Hospital Heidelberg Germany; National Center for Tumor Diseases (NCT), Heidelberg University Hospital Heidelberg Germany
Description
n/a
Files
fulltext.pdf
Files
(1.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:9208cf45288a2245d537e1a5ac3b5fdf
|
1.7 MB | Preview Download |